Prospective single-centre, observational study with medical products. Patients with a medical history of SVT will be observed for at least 24 months after inclusion. The study will begin when the patient is referred to our centre for SVT and will end at the 24-month follow-up or at the occurrence of a study outcome event, or in case of Death OBJECTIVE: To prospectively define the incidence of recurrent thrombosis and bleeding events during anticoagulant therapy in patients with diagnosed SVT, regardless of whether they will be hospitalized or treated as outpatients
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Incidenze of bleedings events
Timeframe: through study completion, an average of 1 year
Incidence of venous and arterial thromboembolic events
Timeframe: through study completion, an average of 1 year
Rate of progress /stable /regressive
Timeframe: every six months, up to 2 years
incidence of liver related events
Timeframe: through study completion, an average of 1 year